After HER2 binding and internalization (or via bystander diffusion), the ADC releases deruxtecan, which inhibits topoisomerase I in the cell, causing DNA damage, cell‑cycle arrest, and apoptosis. Top1 is not the antibody-recognized target, but the intracellular enzymatic target of the payload.